United States Immuno-Oncology Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Immuno-Oncology Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Immuno-Oncology Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Immuno-Oncology Overall Market Size
2.1 United States Immuno-Oncology Market Size: 2021 VS 2027
2.2 United States Immuno-Oncology Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Immuno-Oncology Players in United States Market
3.2 Top United States Immuno-Oncology Companies Ranked by Revenue
3.3 United States Immuno-Oncology Revenue by Companies
3.4 Top 3 and Top 5 Immuno-Oncology Companies in United States Market, by Revenue in 2020
3.5 Companies Immuno-Oncology Product Type
3.6 Tier 1, Tier 2 and Tier 3 Immuno-Oncology Players in United States Market
3.6.1 List of Tier 1 Immuno-Oncology Companies in United States
3.6.2 List of Tier 2 and Tier 3 Immuno-Oncology Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Immuno-Oncology Market Size Markets, 2021 & 2027
4.1.2 Immune Checkpoint Inhibitors
4.1.3 Cytokine-Based Immunotherapy
4.1.4 Cancer Vaccines
4.1.5 CAR-T Cell Therapy
4.1.6 Others
4.2 By Type - United States Immuno-Oncology Revenue & Forecasts
4.2.1 By Type - United States Immuno-Oncology Revenue, 2016-2021
4.2.2 By Type - United States Immuno-Oncology Revenue, 2022-2027
4.2.3 By Type - United States Immuno-Oncology Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Immuno-Oncology Market Size, 2021 & 2027
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application - United States Immuno-Oncology Revenue & Forecasts
5.2.1 By Application - United States Immuno-Oncology Revenue, 2016-2021
5.2.2 By Application - United States Immuno-Oncology Revenue, 2022-2027
5.2.3 By Application - United States Immuno-Oncology Revenue Market Share, 2016-2027
6 Immuno-Oncology Companies Profiles
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Company Details
6.1.2 Bristol-Myers Squibb Business Overview
6.1.3 Bristol-Myers Squibb Immuno-Oncology Introduction
6.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue in United States Market (2016-2021)
6.1.5 Bristol-Myers Squibb Recent Developments
6.2 Merck & Co., Inc.
6.2.1 Merck & Co., Inc. Company Details
6.2.2 Merck & Co., Inc. Business Overview
6.2.3 Merck & Co., Inc. Immuno-Oncology Introduction
6.2.4 Merck & Co., Inc. Immuno-Oncology Revenue in United States Market (2016-2021)
6.2.5 Merck & Co., Inc. Recent Developments
6.3 Roche AG
6.3.1 Roche AG Company Details
6.3.2 Roche AG Business Overview
6.3.3 Roche AG Immuno-Oncology Introduction
6.3.4 Roche AG Immuno-Oncology Revenue in United States Market (2016-2021)
6.3.5 Roche AG Recent Developments
6.4 AstraZeneca, Plc
6.4.1 AstraZeneca, Plc Company Details
6.4.2 AstraZeneca, Plc Business Overview
6.4.3 AstraZeneca, Plc Immuno-Oncology Introduction
6.4.4 AstraZeneca, Plc Immuno-Oncology Revenue in United States Market (2016-2021)
6.4.5 AstraZeneca, Plc Recent Developments
6.5 Sanofi S.A.
6.5.1 Sanofi S.A. Company Details
6.5.2 Sanofi S.A. Business Overview
6.5.3 Sanofi S.A. Immuno-Oncology Introduction
6.5.4 Sanofi S.A. Immuno-Oncology Revenue in United States Market (2016-2021)
6.5.5 Sanofi S.A. Recent Developments
6.6 Dendreon Pharmaceuticals
6.6.1 Dendreon Pharmaceuticals Company Details
6.6.2 Dendreon Pharmaceuticals Business Overview
6.6.3 Dendreon Pharmaceuticals Immuno-Oncology Introduction
6.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue in United States Market (2016-2021)
6.6.5 Dendreon Pharmaceuticals Recent Developments
6.7 Novartis
6.7.1 Novartis Company Details
6.7.2 Novartis Business Overview
6.7.3 Novartis Immuno-Oncology Introduction
6.7.4 Novartis Immuno-Oncology Revenue in United States Market (2016-2021)
6.7.5 Novartis Recent Developments
6.8 Gilead Sciences Inc.
6.8.1 Gilead Sciences Inc. Company Details
6.8.2 Gilead Sciences Inc. Business Overview
6.8.3 Gilead Sciences Inc. Immuno-Oncology Introduction
6.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue in United States Market (2016-2021)
6.8.5 Gilead Sciences Inc. Recent Developments
6.9 Merck KGaA
6.9.1 Merck KGaA Company Details
6.9.2 Merck KGaA Business Overview
6.9.3 Merck KGaA Immuno-Oncology Introduction
6.9.4 Merck KGaA Immuno-Oncology Revenue in United States Market (2016-2021)
6.9.5 Merck KGaA Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. Immuno-Oncology Market Opportunities & Trends in United States Market
Table 2. Immuno-Oncology Market Drivers in United States Market
Table 3. Immuno-Oncology Market Restraints in United States Market
Table 4. Key Players of Immuno-Oncology in United States Market
Table 5. Top Immuno-Oncology Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Immuno-Oncology Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Immuno-Oncology Revenue Share by Companies, 2016-2021
Table 8. Companies Immuno-Oncology Product Type
Table 9. List of Tier 1 Immuno-Oncology Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Immuno-Oncology Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - United States Immuno-Oncology Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Immuno-Oncology Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Immuno-Oncology Revenue (US$, Mn), 2022-2027
Table 14. By Application - United States Immuno-Oncology Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Immuno-Oncology Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Immuno-Oncology Revenue (US$, Mn), 2022-2027
Table 17. Bristol-Myers Squibb Company Details
Table 18. Bristol-Myers Squibb Business Overview
Table 19. Bristol-Myers Squibb Immuno-Oncology Product
Table 20. Bristol-Myers Squibb Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. Bristol-Myers Squibb Recent Developments
Table 22. Merck & Co., Inc. Company Details
Table 23. Merck & Co., Inc. Business Overview
Table 24. Merck & Co., Inc. Immuno-Oncology Product
Table 25. Merck & Co., Inc. Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Merck & Co., Inc. Recent Developments
Table 27. Roche AG Company Details
Table 28. Roche AG Business Overview
Table 29. Roche AG Immuno-Oncology Product
Table 30. Roche AG Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. Roche AG Recent Developments
Table 32. AstraZeneca, Plc Company Details
Table 33. AstraZeneca, Plc Business Overview
Table 34. AstraZeneca, Plc Immuno-Oncology Product
Table 35. AstraZeneca, Plc Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. AstraZeneca, Plc Recent Developments
Table 37. Sanofi S.A. Company Details
Table 38. Sanofi S.A. Business Overview
Table 39. Sanofi S.A. Immuno-Oncology Product
Table 40. Sanofi S.A. Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Sanofi S.A. Recent Developments
Table 42. Dendreon Pharmaceuticals Company Details
Table 43. Dendreon Pharmaceuticals Business Overview
Table 44. Dendreon Pharmaceuticals Immuno-Oncology Product
Table 45. Dendreon Pharmaceuticals Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. Dendreon Pharmaceuticals Recent Developments
Table 47. Novartis Company Details
Table 48. Novartis Business Overview
Table 49. Novartis Immuno-Oncology Product
Table 50. Novartis Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. Novartis Recent Developments
Table 52. Gilead Sciences Inc. Company Details
Table 53. Gilead Sciences Inc. Business Overview
Table 54. Gilead Sciences Inc. Immuno-Oncology Product
Table 55. Gilead Sciences Inc. Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Gilead Sciences Inc. Recent Developments
Table 57. Merck KGaA Company Details
Table 58. Merck KGaA Business Overview
Table 59. Merck KGaA Immuno-Oncology Product
Table 60. Merck KGaA Immuno-Oncology Revenue in United States Market (2016-2021) & (US$ Million)
Table 61. Merck KGaA Recent Developments
List of FiguresFigure 1. Immuno-Oncology Segment by Type
Figure 2. Immuno-Oncology Segment by Application
Figure 3. United States Immuno-Oncology Market Overview: 2020
Figure 4. United States Immuno-Oncology Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Immuno-Oncology Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Immuno-Oncology Revenue in 2020
Figure 7. By Type - United States Immuno-Oncology Revenue Market Share, 2016-2027
Figure 8. By Application - United States Immuno-Oncology Revenue Market Share, 2016-2027
Figure 9. Bristol-Myers Squibb Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Merck & Co., Inc. Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Roche AG Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. AstraZeneca, Plc Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Sanofi S.A. Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Dendreon Pharmaceuticals Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Novartis Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Gilead Sciences Inc. Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 17. Merck KGaA Immuno-Oncology Revenue Year Over Year Growth (US$, Mn) & (2016-2021)